Long-term patient survival in ANCA-associated vasculitis

Research output: Contribution to journalArticle

Standard

Long-term patient survival in ANCA-associated vasculitis. / Flossmann, O; Berden, A; de Groot, K; Hagen, C; Harper, Lorraine; Heijl, C; Hoglund, P; Jayne, D; Luqmani, R; Mahr, A; Mukhtyar, C; Pusey, C; Rasmussen, N; Stegeman, C; Walsh, M; Westman, K.

In: Annals of the Rheumatic Diseases, Vol. 70, No. 3, 01.03.2011, p. 488-494.

Research output: Contribution to journalArticle

Harvard

Flossmann, O, Berden, A, de Groot, K, Hagen, C, Harper, L, Heijl, C, Hoglund, P, Jayne, D, Luqmani, R, Mahr, A, Mukhtyar, C, Pusey, C, Rasmussen, N, Stegeman, C, Walsh, M & Westman, K 2011, 'Long-term patient survival in ANCA-associated vasculitis', Annals of the Rheumatic Diseases, vol. 70, no. 3, pp. 488-494. https://doi.org/10.1136/ard.2010.137778

APA

Flossmann, O., Berden, A., de Groot, K., Hagen, C., Harper, L., Heijl, C., Hoglund, P., Jayne, D., Luqmani, R., Mahr, A., Mukhtyar, C., Pusey, C., Rasmussen, N., Stegeman, C., Walsh, M., & Westman, K. (2011). Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 70(3), 488-494. https://doi.org/10.1136/ard.2010.137778

Vancouver

Author

Flossmann, O ; Berden, A ; de Groot, K ; Hagen, C ; Harper, Lorraine ; Heijl, C ; Hoglund, P ; Jayne, D ; Luqmani, R ; Mahr, A ; Mukhtyar, C ; Pusey, C ; Rasmussen, N ; Stegeman, C ; Walsh, M ; Westman, K. / Long-term patient survival in ANCA-associated vasculitis. In: Annals of the Rheumatic Diseases. 2011 ; Vol. 70, No. 3. pp. 488-494.

Bibtex

@article{a8f3fd7b519042de9e1833002bfbc141,
title = "Long-term patient survival in ANCA-associated vasculitis",
abstract = "Background Wegener's granulomatosis and microscopic polyangiitis are antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides with significant morbidity and mortality. The long-term survival of patients with ANCA associated vasculitis treated with current regimens is uncertain. Objective To describe the long-term patient survival and possible prognostic factors at presentation in an international, multicentre, prospectively recruited representative patient cohort who were treated according to strictly defined protocols at presentation and included the full spectrum of ANCA-associated vasculitis disease. Methods Outcome data were collected for 535 patients who had been recruited at the time of diagnosis to four randomised controlled trials between 1995 and 2002. Trial eligibility was defined by disease severity and extent, covered the spectrum of severity of ANCA-associated vasculitis and used consistent diagnostic criteria. Demographic, clinical and laboratory parameters at trial entry were tested as potential prognostic factors in multivariable models. Results The median duration of follow-up was 5.2 years and 133 (25%) deaths were recorded. Compared with an age-and sex-matched general population there was a mortality ratio of 2.6 (95% CI 2.2 to 3.1). Main causes of death within the first year were infection (48%) and active vasculitis (19%). After the first year the major causes of death were cardiovascular disease (26%), malignancy (22%) and infection (20%). Multivariable analysis showed an estimated glomerular filtration rate ",
author = "O Flossmann and A Berden and {de Groot}, K and C Hagen and Lorraine Harper and C Heijl and P Hoglund and D Jayne and R Luqmani and A Mahr and C Mukhtyar and C Pusey and N Rasmussen and C Stegeman and M Walsh and K Westman",
year = "2011",
month = mar
day = "1",
doi = "10.1136/ard.2010.137778",
language = "English",
volume = "70",
pages = "488--494",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - Long-term patient survival in ANCA-associated vasculitis

AU - Flossmann, O

AU - Berden, A

AU - de Groot, K

AU - Hagen, C

AU - Harper, Lorraine

AU - Heijl, C

AU - Hoglund, P

AU - Jayne, D

AU - Luqmani, R

AU - Mahr, A

AU - Mukhtyar, C

AU - Pusey, C

AU - Rasmussen, N

AU - Stegeman, C

AU - Walsh, M

AU - Westman, K

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background Wegener's granulomatosis and microscopic polyangiitis are antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides with significant morbidity and mortality. The long-term survival of patients with ANCA associated vasculitis treated with current regimens is uncertain. Objective To describe the long-term patient survival and possible prognostic factors at presentation in an international, multicentre, prospectively recruited representative patient cohort who were treated according to strictly defined protocols at presentation and included the full spectrum of ANCA-associated vasculitis disease. Methods Outcome data were collected for 535 patients who had been recruited at the time of diagnosis to four randomised controlled trials between 1995 and 2002. Trial eligibility was defined by disease severity and extent, covered the spectrum of severity of ANCA-associated vasculitis and used consistent diagnostic criteria. Demographic, clinical and laboratory parameters at trial entry were tested as potential prognostic factors in multivariable models. Results The median duration of follow-up was 5.2 years and 133 (25%) deaths were recorded. Compared with an age-and sex-matched general population there was a mortality ratio of 2.6 (95% CI 2.2 to 3.1). Main causes of death within the first year were infection (48%) and active vasculitis (19%). After the first year the major causes of death were cardiovascular disease (26%), malignancy (22%) and infection (20%). Multivariable analysis showed an estimated glomerular filtration rate

AB - Background Wegener's granulomatosis and microscopic polyangiitis are antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides with significant morbidity and mortality. The long-term survival of patients with ANCA associated vasculitis treated with current regimens is uncertain. Objective To describe the long-term patient survival and possible prognostic factors at presentation in an international, multicentre, prospectively recruited representative patient cohort who were treated according to strictly defined protocols at presentation and included the full spectrum of ANCA-associated vasculitis disease. Methods Outcome data were collected for 535 patients who had been recruited at the time of diagnosis to four randomised controlled trials between 1995 and 2002. Trial eligibility was defined by disease severity and extent, covered the spectrum of severity of ANCA-associated vasculitis and used consistent diagnostic criteria. Demographic, clinical and laboratory parameters at trial entry were tested as potential prognostic factors in multivariable models. Results The median duration of follow-up was 5.2 years and 133 (25%) deaths were recorded. Compared with an age-and sex-matched general population there was a mortality ratio of 2.6 (95% CI 2.2 to 3.1). Main causes of death within the first year were infection (48%) and active vasculitis (19%). After the first year the major causes of death were cardiovascular disease (26%), malignancy (22%) and infection (20%). Multivariable analysis showed an estimated glomerular filtration rate

U2 - 10.1136/ard.2010.137778

DO - 10.1136/ard.2010.137778

M3 - Article

C2 - 21109517

VL - 70

SP - 488

EP - 494

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 3

ER -